AGN News and Press, Allergan plc From 04/10/19

DUBLIN , April 10, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has received the 2019 ENERGY STAR ® Partner of the Year Sustained Excellence Award for its continued leadership in energy management and efficiency. The...

DUBLIN , April 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019 , prior to the open of U.S. Financial Markets. Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time...

Market Assessment Novartis AG ( NVS ) is a Swiss (Basel, Switzerland) multi-billion biopharmaceutical company with a market cap of $217 billion and a broad therapeutic portfolio that encompasses many facets of biomedical science, including immunology, oncology, respiratory, neuroscience, o...

DUBLIN , April 8, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today released the results of their first-of-its-kind worldwide medical aesthetics study, titled the Allergan 360 °  Aesthetics Report, exploring the mindset and motivations of aesthetically conscious consumers ...

Author’s note: I am grateful to Dr. Pascaline Clerc, U.S Campaign Manager, The National Education Program. Introduction 2019, designated as the year of NASH in the biotech industry, was the year to demonstrate the clinical achievements in NASH therapeutics. In the beginning of...

In a return salvo to Allergan's ( AGN +2.6% ) proxy statement filed two days ago urging shareholders to vote against its proposal to split the Chairman and CEO roles currently held by Brent Saunders, activist investor Appaloosa LP has filed a supplemental presentation (re)emphasizing t...

Allergan's latest hyaluronic acid injectable gel uses the patented VYCROSS® technology and is specifically formulated to restore and create volume(1) Juvéderm® VOLUX allows practitioners to sculpt the chin and jaw area,(2) giving facial definition that can last for up to 1...

Results from a 28-week open-label study, MAPLE, evaluating Allergan (NYSE: AGN ) and licensor Molecular Partners' ( OTCPK:MLLCF ) abicipar in 123 patients with age-related neovascular macular degeneration (nAMD) showed an improved safety profile after the manufacturing process was modifie...

DUBLIN , April 2, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin ® therapies, today announced topline safety resul...

Allergan ( AGN ) originally received FDA approval for Botox type A in 2002, derived from botulinum toxin, made by the bacteria that causes botulism (clostridium botulinum). Many are familiar with the cosmetic uses of Botox (onabotulinum toxin A), but not so many are familiar with the medical u...